Skip to content

PHARMA-BIO SERV, INC.: 10-Q filed 2015-09-14

What PHARMA-BIO SERV, INC. reported in its quarterly report filed 2015-09-14 (fiscal Q3 2015): 33 published measures, 110 facts as tagged in accession 0001354488-15-004283.

This filing

Form
10-Q (quarterly report)
Filed
2015-09-14
Fiscal period
fiscal Q3 2015
Accession
0001354488-15-004283 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PHARMA-BIO SERV, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-07-3123,311,987USD
At 2014-10-3123,211,084USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-07-311,810,306USD
At 2014-10-312,700,323USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-07-3121,501,681USD
At 2014-10-3120,510,761USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-07-3114,007,856USD
At 2015-04-3014,405,483USD
At 2014-10-3115,088,070USD
At 2014-07-3113,796,618USD
At 2014-04-3012,828,589USD
At 2013-10-3112,045,923USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-05-01 to 2015-07-31453,973USD92
2014-11-01 to 2015-07-311,101,373USD273
2014-05-01 to 2014-07-31597,060USD92
2013-11-01 to 2014-07-311,586,771USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2015-05-01 to 2015-07-31-348,936USD92
2014-11-01 to 2015-07-31-799,311USD273
2014-05-01 to 2014-07-311,095,684USD92
2013-11-01 to 2014-07-311,965,114USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2015-05-01 to 2015-07-3133,096USD92
2014-11-01 to 2015-07-31102,279USD273
2014-05-01 to 2014-07-31106,208USD92
2013-11-01 to 2014-07-31171,820USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2015-05-01 to 2015-07-31-13,597USD92
2014-11-01 to 2015-07-31-143,538USD273
2014-05-01 to 2014-07-31-12,639USD92
2013-11-01 to 2014-07-31-33,292USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2015-05-01 to 2015-07-31-33,096USD92
2014-11-01 to 2015-07-31-102,279USD273
2014-05-01 to 2014-07-31-106,208USD92
2013-11-01 to 2014-07-31-171,820USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-07-3120,708,177USD
At 2014-10-3119,606,817USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2015-05-01 to 2015-07-3123,071,400shares92
2014-11-01 to 2015-07-3123,077,736shares273
2014-05-01 to 2014-07-3123,049,212shares92
2013-11-01 to 2014-07-3122,957,160shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2015-05-01 to 2015-07-3123,354,538shares92
2014-11-01 to 2015-07-3123,433,467shares273
2014-05-01 to 2014-07-3123,609,317shares92
2013-11-01 to 2014-07-3123,715,758shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2015-05-01 to 2015-07-310.02USD/shares92
2014-11-01 to 2015-07-310.048USD/shares273
2014-05-01 to 2014-07-310.026USD/shares92
2013-11-01 to 2014-07-310.069USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2015-05-01 to 2015-07-310.019USD/shares92
2014-11-01 to 2015-07-310.047USD/shares273
2014-05-01 to 2014-07-310.025USD/shares92
2013-11-01 to 2014-07-310.067USD/shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2015-05-01 to 2015-07-3141,135USD92
2014-11-01 to 2015-07-31112,189USD273
2014-05-01 to 2014-07-31100,391USD92
2013-11-01 to 2014-07-31356,712USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2015-07-31696,648USD
At 2014-10-31869,041USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-05-01 to 2015-07-3121,000USD92
2014-11-01 to 2015-07-31107,448USD273
2014-05-01 to 2014-07-3117,100USD92
2013-11-01 to 2014-07-3151,300USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-05-01 to 2015-07-31495,322USD92
2014-11-01 to 2015-07-311,215,758USD273
2014-05-01 to 2014-07-31698,260USD92
2013-11-01 to 2014-07-311,945,143USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-07-3122,595,278USD
At 2014-10-3122,324,988USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-07-311,752,524USD
At 2014-10-312,625,587USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2015-07-317,680,494USD
At 2014-10-316,385,575USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2015-05-01 to 2015-07-318,212USD92
2014-11-01 to 2015-07-31127,018USD273
2014-05-01 to 2014-07-312,280USD92
2013-11-01 to 2014-07-312,280USD273

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2015-05-01 to 2015-07-312,046,237USD92
2014-11-01 to 2015-07-315,437,580USD273
2014-05-01 to 2014-07-312,178,236USD92
2013-11-01 to 2014-07-316,640,351USD273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2015-05-01 to 2015-07-311,550,915USD92
2014-11-01 to 2015-07-314,221,822USD273
2014-05-01 to 2014-07-311,479,976USD92
2013-11-01 to 2014-07-314,695,208USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-07-3123,066,450shares
At 2014-10-3123,033,912shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2015-07-31-226,592USD
At 2014-10-31-135,708USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2015-07-312,477,734USD
At 2014-10-312,204,009USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2015-07-3120,061USD
At 2014-10-3117,055USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2015-05-01 to 2015-07-31495,108USD92
2014-11-01 to 2015-07-311,213,562USD273
2014-05-01 to 2014-07-31697,451USD92
2013-11-01 to 2014-07-311,943,483USD273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2015-05-01 to 2015-07-31434,254USD92
2014-11-01 to 2015-07-311,010,489USD273
2014-05-01 to 2014-07-31571,779USD92
2013-11-01 to 2014-07-311,563,678USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2015-05-01 to 2015-07-3190,075USD92
2014-11-01 to 2015-07-31273,725USD273
2014-05-01 to 2014-07-3193,882USD92
2013-11-01 to 2014-07-31281,387USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2015-05-01 to 2015-07-31-214USD92
2014-11-01 to 2015-07-31-2,196USD273
2014-05-01 to 2014-07-31-809USD92
2013-11-01 to 2014-07-31-1,660USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2015-05-01 to 2015-07-31578,601USD92
2014-11-01 to 2015-07-311,314,222USD273
2014-05-01 to 2014-07-31-631,762USD92
2013-11-01 to 2014-07-31-1,038,841USD273

Inspect the source

Entity
PHARMA-BIO SERV, INC. / CIK 0001304161
Captured
2026-09-19T11:17:27.241Z
SEC response SHA-256
bc9f33e072a9daa74aa0e8c41fbfef83d107920bc25647db80386f28787f2d49

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001304161.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))